Cerevast Medical, Inc.
http://cerevast.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cerevast Medical, Inc.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Pacts In Medtech: Glaukos To Distribute Saten's MicroShunt; Acell Signs Distribution Deals
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
Phase III Trial Of Cerevast’s Transcranial Ultrasound To Treat Stroke Misses Endpoint
The 90-day results of CLOTBUST ER, published in The Lancet, show sonothrombolysis to treat acute ischemic stroke is feasible and probably safe, but the trial did not show a clinical benefit of the therapy in conjunction with alteplase treatment.
Appointments: Astellas, BIO, Hikma, Eton, Akili and Oxford BioDynamics
This week's roundup includes CEO appointments by Eton Pharmaceuticals, the Biotechnology Innovation Organization and Hikma, in addition to various other high-level appointments by Astellas, Akili Interactive Labs and Oxford BioDynamics.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Rehabilitation Equipment and Devices
-
Diagnostic Imaging Equipment & Supplies
- Ultrasound
- Other Names / Subsidiaries
-
- Cerevast Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice